Literature DB >> 27603129

Obesity: will withaferin win the war?

Paul T Pfluger1, Matthias H Tschöp1,2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27603129     DOI： 10.1038/nm.4182

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

Review 1.  Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.

Authors:  Huanjie Yang; Q Ping Dou
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

2.  Treatment of obesity with celastrol.

Authors:  Junli Liu; Jaemin Lee; Mario Andres Salazar Hernandez; Ralph Mazitschek; Umut Ozcan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

Review 3.  Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.

Authors:  Matthias H Tschöp; Brian Finan; Christoffer Clemmensen; Vasily Gelfanov; Diego Perez-Tilve; Timo D Müller; Richard D DiMarchi
Journal:  Cell Metab       Date:  2016-07-12       Impact factor: 27.287

4.  Anti-cancer activity of withaferin A in B-cell lymphoma.

Authors:  M K McKenna; B W Gachuki; S S Alhakeem; K N Oben; V M Rangnekar; R C Gupta; S Bondada
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Challenges and opportunities of defining clinical leptin resistance.

Authors:  Martin G Myers; Steven B Heymsfield; Carol Haft; Barbara B Kahn; Maren Laughlin; Rudolph L Leibel; Matthias H Tschöp; Jack A Yanovski
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

6.  Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity.

Authors:  Xiaoqing Zhang; Guo Zhang; Hai Zhang; Michael Karin; Hua Bai; Dongsheng Cai
Journal:  Cell       Date:  2008-10-03       Impact factor: 41.582

7.  Leptin regulation of Hsp60 impacts hypothalamic insulin signaling.

Authors:  André Kleinridders; Hans P M M Lauritzen; Siegfried Ussar; Jane H Christensen; Marcelo A Mori; Peter Bross; C Ronald Kahn
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

8.  Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1α Transcriptional Axis.

Authors:  Xinran Ma; Lingyan Xu; Anna Teresa Alberobello; Oksana Gavrilova; Alessia Bagattin; Monica Skarulis; Jie Liu; Toren Finkel; Elisabetta Mueller
Journal:  Cell Metab       Date:  2015-09-03       Impact factor: 27.287

9.  Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice.

Authors:  Jaemin Lee; Junli Liu; Xudong Feng; Mario Andrés Salazar Hernández; Patrick Mucka; Dorina Ibi; Jae Won Choi; Umut Ozcan
Journal:  Nat Med       Date:  2016-08-01       Impact factor: 53.440

10.  Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice.

Authors:  Jung Eun Kim; Mi Hwa Lee; Deok Hwa Nam; Hye Kyoung Song; Young Sun Kang; Ji Eun Lee; Hyun Wook Kim; Jin Joo Cha; Young Youl Hyun; Sang Youb Han; Kum Hyun Han; Jee Young Han; Dae Ryong Cha
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240
  10 in total
  2 in total

1.  Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC.

Authors:  Varsha D Shiragannavar; Nirmala G Sannappa Gowda; Divya P Kumar; Faridoddin Mirshahi; Prasanna K Santhekadur
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

2.  Integrity of Ayurveda.

Authors:  Bhushan Patwardhan
Journal:  J Ayurveda Integr Med       Date:  2016-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.